About Altis Biosystems
Altis Biosystems is a company based in Durham (United States) founded in 2015 by Scott Magness, Nancy Allbritton, Michael Biron, Yuli Wang, and Christopher Sims. Altis Biosystems has raised $7.53 million across 15 funding rounds from investors including HHS, NCBiotech and Atlanta Technology Angels. Altis Biosystems offers products and services including RepliGut® Kits, Custom InflammaScreen, and StemTox. Altis Biosystems operates in a competitive market with competitors including Toxys, ATANIS Biotech, Inovotion, ABL Diagnostics and BioTalentum, among others.
- Headquarter Durham, United States
- Founders Scott Magness, Nancy Allbritton, Michael Biron, Yuli Wang, Christopher Sims
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Altis Biosystems, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.53 M (USD)
in 15 rounds
-
Latest Funding Round
$2.13 M (USD), Seed
Mar 31, 2025
-
Investors
HHS
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Altis Biosystems
Altis Biosystems offers a comprehensive portfolio of products and services, including RepliGut® Kits, Custom InflammaScreen, and StemTox.
Kits for replicating human intestinal structures in drug testing.
Service to evaluate inflammatory effects on intestinal models.
Assay for predicting gastrointestinal toxicity risks in therapeutics.
People of Altis Biosystems
Unlock access to complete
Unlock access to complete
Funding Insights of Altis Biosystems
Altis Biosystems has successfully raised a total of $7.53M across 15 strategic funding rounds. The most recent funding activity was a Seed round of $2.13 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Altis Biosystems
Altis Biosystems has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NCBiotech and Atlanta Technology Angels.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are incubated and funded in North Carolina.
|
Locked | Locked | Locked | |
|
Early-stage ventures in the Southeast are supported by VentureSouth.
|
Locked | Locked | Locked | |
|
Angel investments are provided across Atlanta and Georgia.
|
Locked | Locked | Locked |
Investor details for Altis Biosystems
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Altis Biosystems
Investment portfolio details for Altis Biosystems
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Altis Biosystems
Detailed financials for Altis Biosystems
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Altis Biosystems Comparisons
Peer comparison for Altis Biosystems
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Altis Biosystems
Altis Biosystems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Toxys, ATANIS Biotech, Inovotion, ABL Diagnostics and BioTalentum, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
In vitro genotoxicity testing services are provided using proprietary technology.
|
|
| Locked | Locked | Locked |
Developer of a cell-based assay for the diagnosis of allergies
|
|
| Locked | Locked | Locked |
Provider of in vivo oncology efficacy and toxicity assays for drug discovery and development
|
|
| Locked | Locked | Locked |
Molecular biology assays and kits are developed for microbiology labs.
|
|
| Locked | Locked | Locked |
Human stem-cell technologies for drug testing and toxicology are provided.
|
Detailed competitors of Altis Biosystems
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Altis Biosystems
Complete news archive for Altis Biosystems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Altis Biosystems
Altis Biosystems was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Altis Biosystems is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Michael Biron is the current CEO of Altis Biosystems. They have also founded this company.
Altis Biosystems is a funded company, having raised a total of $7.53M across 15 funding rounds to date.
Altis Biosystems was founded in 2015 in Durham, United States, focusing on biotechnology for drug development. A stem cell-derived platform called RepliGut is utilized to assess drug disposition, including toxicity, metabolism, absorption, and efficacy. Operations center on in vitro modeling to support pharmaceutical research, with services aimed at improving drug safety and performance evaluations.
Altis Biosystems's top competitors include ABL Diagnostics, ATANIS Biotech and Toxys.
Altis Biosystems offers RepliGut® Kits, Custom InflammaScreen, and StemTox.
Altis Biosystems has 8 investors. Key investors include HHS, NCBiotech, Atlanta Technology Angels, VentureSouth, and Central Texas Angel Network.